| Literature DB >> 21822481 |
Yoshinori Nishimoto1, Shigeaki Suzuki, Kimiaki Utsugisawa, Yuriko Nagane, Mamoru Shibata, Toshihiko Shimizu, Norihiro Suzuki.
Abstract
Myasthenia gravis (MG) patients visiting outpatient clinics frequently complain of headache. However, there have been few reports on the relation between chronic headache and myasthenia gravis (MG). We aimed to investigate whether MG symptoms affect the development or worsening of chronic headache. Among the 184 MG patients who were followed at the MG clinics, tension-type headache was observed in 71 (38.6%) patients and 9 (4.9%) complained of migraine. Twenty-five (13.6%) complained that headache appeared or was exacerbated after the MG onset. The investigation into differences in the clinical characteristics of the MG patients showed that women tended to suffer from MG-associated headache more often than men. Logistic regression analyses revealed that female gender and mild ocular symptoms were independently predictive of headache associated with MG. Our results suggest that treatment of chronic headache should be required to improve the quality of life in MG patients.Entities:
Year: 2011 PMID: 21822481 PMCID: PMC3148594 DOI: 10.4061/2011/840364
Source DB: PubMed Journal: Autoimmune Dis ISSN: 2090-0430
Figure 1The characteristics of MG-associated headache. (a) The frequency of headache associated with MG (N = 25). (b) The rates of the patients, who complained of MG-associated headache in each site. Note that headache associated with MG occurs deeply in the orbit most frequently.
Demographic and clinical features of patients with MG-associated headache.
| MG-associated headache (+) ( | MG-associated headache (−) ( | ||
|---|---|---|---|
| Female gender | 22 (88%) | 102 (64%) | *0.03 |
| Mean age, y (range) | 49.4 ± 17.2 | 57.0 ± 16.8 | n.s. |
| Mean disease duration, y (range) | 9.2 ± 7.6 | 8.2 ± 8.2 | n.s. |
| AChR-Ab positive | 16 (64%) | 118 (74%) | n.s. |
| Thymoma present | 2 (8%) | 37 (23%) | n.s. |
| Thymectomy | 9 (36%) | 74 (47%) | n.s. |
| PSL administration | 15 (60%) | 84 (53%) | n.s. |
| CNI administration | 8 (32%) | 43 (27%) | n.s. |
| QMG scores | |||
| Total | 8.4 ± 4.9 | 6.2 ± 4.6 | n.s. |
| Ocular symptoms | 2.2 ± 1.6 | 1.6 ± 1.8 | n.s. |
| Bulbar symptoms | 0.3 ± 0.5 | 0.2 ± 0.6 | n.s. |
| Limb symptoms | 4.9 ± 3.0 | 3.7 ± 2.8 | n.s. |
| Trunk symptoms | 1.1 ± 0.7 | 0.8 ± 0.8 | n.s. |
*P-value < 0.05.
MG: myasthenia gravis; QMG: quantitative myasthenia gravis scoring; n.s.: not significant; AChR-Ab, autoantibodies to the acetylcholine receptor; PSL: prednisolone; CNI: calcineurin inhibitor.
Influences of clinical factors on headache associated with MG.
| Variable | Odds ratio (95% CI) | |
|---|---|---|
| Age (years) | 1.0 (0.9–1.0) | n.s. |
| Female gender | 4.5 (1.2–16.8) | *0.02 |
| Age at onset (years) | 1.0 (1.0–1.1) | n.s. |
| Mild ocular symptoms (QMG 1-3) | 7.2 (2.4–21.8) | *0.0005 |
| Mild bulbar symptoms (QMG 1-3) | 2.3 (0.4–14.6) | n.s. |
| Total QMG score | 1.1 (0.9–1.3) | n.s. |
*P-value < 0.05.
MG: myasthenia gravis; n.s.: not significant; QMG: quantitative myasthenia gravis scoring; CI: confidence interval.